Moleculin Biotech Inc. (NASDAQ: MBRX) will present data on its ongoing Phase 3 clinical trial for acute myeloid leukemia at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE